Trials / Completed
CompletedNCT06477926
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
A Phase 1 Relative Bioavailability and Food Effect Study of ABBV-668 Extended-Release Formulations
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-668 IR | • Oral Capsule |
| DRUG | ABBV-668 ER | • Oral Tablets |
Timeline
- Start date
- 2024-07-09
- Primary completion
- 2024-09-20
- Completion
- 2024-09-20
- First posted
- 2024-06-27
- Last updated
- 2024-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06477926. Inclusion in this directory is not an endorsement.